Cargando…
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
Patients with acute medical illnesses are at increased risk of venous thromboembolism (VTE), a significant cause of morbidity and mortality. Thromboprophylaxis is recommended in these patients but questions remain regarding the optimal duration of therapy. The aim of this study is to determine wheth...
Autores principales: | Cohen, Alexander Thomas, Spiro, Theodore Erich, Büller, Harry Roger, Haskell, Lloyd, Hu, Dayi, Hull, Russell, Mebazaa, Alexandre, Merli, Geno, Schellong, Sebastian, Spyropoulos, Alex, Tapson, Victor |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090572/ https://www.ncbi.nlm.nih.gov/pubmed/21359646 http://dx.doi.org/10.1007/s11239-011-0549-x |
Ejemplares similares
-
Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021) -
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2022) -
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the
MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019) -
Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022) -
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)